Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tempus AI
TEM
5
Block
XYZ
US Stock MarketDetailed Quotes
Intellia Therapeutics (NTLA)
- 12.500
- +0.630+5.31%
Close Jan 16 16:00 ET
- 12.500
- 0.0000.00%
Post 19:58 ET
1.45BMarket Cap-2.94P/E (TTM)
12.750High11.700Low5.75MVolume11.880Open11.870Prev Close71.58MTurnover5.22%Turnover RatioLossP/E (Static)115.83MShares28.25052wk High1.93P/B1.38BFloat Cap5.90052wk Low--Dividend TTM110.20MShs Float202.730Historical High--Div Yield TTM8.85%Range %5.900Historical Low12.450Avg Price1Lot Size
About Intellia Therapeutics Company
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Company Profile
SymbolNTLA
Company NameIntellia Therapeutics
Listing DateMay 6, 2016
Issue Price18.00
ISINUS45826J1051
Founded2014
CEODr. John M. Leonard, M.D.
MarketNASDAQ
Employees403
Fiscal Year Ends12-31
Address40 Erie Street,Suite 130
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02139
Phone1-857-285-6200
Websitehttp://www.intelliatx.com
Company Executives
- Name
- Position
- Salary
- Dr. John M. Leonard, M.D.
- Director, President and Chief Executive Officer
- 15.33M
- Birgit Schultes
- Executive Vice President and Chief Scientific Officer
- --
- Eliana Clark
- Executive Vice President and Chief Technology Officer
- --
- Michael P. Dube
- Vice President and Chief Accounting Officer
- 1.34M
- Edward J. Dulac, III
- Treasurer, Executive Vice President and Chief Financial Officer
- 6.69M
- Dr. David Lebwohl, M.D.
- Executive Vice President and Chief Medical Officer
- 5.58M
- James Basta, J.D.
- Executive Vice President, General Counsel and Corporate Secretary
- 4.87M
- Dr. Frank Verwiel, M.B.A.,M.D.
- Chairman of the Board
- 499.93K
- Muna Bhanji, Ph.
- Independent Director
- 467.66K
- William J. Chase
- Independent Director
- 479.93K
- Brian Goff
- Independent Director
- 828.75K
- Dr. Jesse Goodman, M.D.,M.P.H.
- Independent Director
- 460.83K
- Dr. Georgia Keresty, M.P.H.,PhD
- Independent Director
- 464.94K
- Dr. Fred E. Cohen, D.Phil.,F.A.C.P.,M.D.
- Independent Director
- 457.88K
Market Insights
Nancy Pelosi Portfolio Nancy Pelosi Portfolio
Former U.S. House Speaker Pelosi, renowned as the "Stock Market Queen" in politics, concentrates her investment portfolio on tech giants in AI and semiconductors. Her core strategy involves purchasing call options for leveraged trading to maximize potential returns. Former U.S. House Speaker Pelosi, renowned as the "Stock Market Queen" in politics, concentrates her investment portfolio on tech giants in AI and semiconductors. Her core strategy involves purchasing call options for leveraged trading to maximize potential returns.
China Concept Stocks China Concept Stocks
Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation. Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation.
View More
Hot Topics Hot Topics
The Fed Delivers Third Consecutive Rate Cut as Expected! How to Position for Year-End U.S. Equity Ma
On December 19, the Bank of Japan raised interest rates by 25 basis points as expected, in line with market forecasts. On the evening of Dec
今日熱門
Dec 11, 2025 03:27
December FOMC Interest Rate Meeting
牛牛課堂
Dec 19, 2025 12:28
[Opportunity Express] MRVL Continues to Bet on Optical Interconnects: Is Now a Good Time to Enter the Market?